Regulatory exclusivity as a primary intellectual property and commercial asset How can a company take advantage of regulatory exclusivity to launch an open science drug discovery program? Max Morgan et al explain in their paper Ideation and implementation of an open science drug discovery business model - M4K Pharma published in Welcome Open Research this month.   Comparing [...]